부산대학교 도서관

Whole-exome sequencing (WES) revealed the emergence of a novel point mutation in CD19 at CD19 SP neg sp relapse, and RNA sequencing confirmed the negative conversion of CD19 expression. Philadelphia chromosome-like acute lymphoblastic leukemia (Ph-like ALL) is a B-cell ALL (B-ALL) subtype with a dismal prognosis and exhibits an expression profile similar to that of Ph-positive ALL, although the BCR-ABL1 fusion protein is absent [[1]]. However, many cases of CD19 negative (CD19 SP neg sp ) relapses have been reported after CD19-targeted therapy [[4]] and the exact mechanisms are not sufficiently clear. Zhao et al. [[4]] analyzed the mutation status of CD19 SP neg sp relapse cases after blinatumomab treatment and identified frequent point mutations in CD19, which included possible hot spots in amino acid residues 251-269 in CD19. [Extracted from the article]